Her2/neu extracellular domain shedding in uterine serous carcinoma: Implications for immunotherapy with trastuzumab

British Journal of Cancer

Volumn 105, Issue 8, 2011, Pages 1176-1182

  Todeschini, P ^a   Cocco, E ^a   Bellone, S ^a   Varughese, J ^a   Lin, K ^a   Carrara, L ^a   Guzzo, F ^a   Buza, N ^a   Hui, P ^a   Silasi, D A ^a   Ratner, E ^a   Azodi, M ^a   Schwartz, P E ^a   Rutherford, T J ^a   Pecorelli, S ^b   Santin, A D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Her2 neu; Her2 neu extracellular domain (ECD); trastuzumab; uterine serous cancer

Indexed keywords

CHROMIUM; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; ASSAY; CANCER IMMUNOTHERAPY; CARCINOMA CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UTERUS CARCINOMA;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CULTURE MEDIA, CONDITIONED; FEMALE; FLOW CYTOMETRY; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; UTERINE NEOPLASMS;

EID: 80053967881     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.369     Document Type: Article

References (33)

1. Alper O, Yamaguchi K, Hitomi J, Honda S, Matsushima T, Abe K (1990) The presence of c-erbB-2 gene product-related protein in culture medium conditioned by breast cancer cell line SK-BR-3. Cell Growth Differ 1: 591-599
2. Anido J, Scaltriti M, Bech Serra JJ, Santiago Josefat B, Todo FR, Baselga J, Arribas J (2006) Biosynthesis of tumourigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J 25: 3234-3244 (Pubitemid 44106773)
3. Baselga J, Carbonell X, Castañeda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P (2005) Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23: 2162-2171 (Pubitemid 46218708)
4. Bethune-Volters A, Labroquere M, Guepratte S, Hacene K, Neumann R, Carney W, Pichon MF (2004) Longitudinal changes in serum HER-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients. Anticancer Res 24: 1083-1089 (Pubitemid 38624942)
5. Brodowicz T, Wiltschke C, Budinsky AC, Krainer M, Steger GG, Zielinski CC (1997) Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro. Int J Cancer 73: 875-879 (Pubitemid 127483044)
6. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6: 443-446 (Pubitemid 30208162)
7. Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A, Massut́ B, Cortés-Funes H, Lloveras B (2000) Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 6: 2356-2362 (Pubitemid 30399203)
8. D́az-Montes TP, Ji H, Smith Sehdev AE, Zahurak ML, Kurman RJ, Armstrong DK, Bristow RE (2006) Clinical significance of Her-2/neu overexpression in uterine serous carcinoma. Gynecol Oncol 100: 139-144 (Pubitemid 41815063)
9. El-Sahwi K, Bellone S, Cocco E, Cargnelutti M, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD (2010) In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer 102: 134-143
10. Ghedini GC, Ciravolo V, Tortoreto M, Giuffrè S, Bianchi F, Campiglio M, Mortarino M, Figini M, Coliva A, Carcangiu ML, Zambetti M, Piazza T, Ferrini S, Ménard S, Tagliabue E, Pupa SM (2010) Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzu-mab susceptibility. J Cell Physiol 225: 256-265
11. Grushko TA, Filiaci VL, Mundt AJ, Ridderstrale K, Olopade OI, Fleming GF, Gynecologic Oncology Group (2008) An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 108: 3-9 (Pubitemid 350299437)
12. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R (1982) Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 6: 93-108 (Pubitemid 12108965)
13. Hoopmann M, Neumann R, Tanasale T, Schöndorf T (2003) HER-2/neu determination in blood plasma of patients with HER-2/neu overexpressing metastasized breast cancer: a longitudinal study. Antic-ancer Res 23: 1031-1034 (Pubitemid 36750915)
14. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J Clin 60: 277-300
15. Kostler WJ, Schwab B, Singer CF, Neumann R, Rücklinger E, Brodowicz T, Tomek S, Niedermayr M, Hejna M, Steger GG, Krainer M, Wiltschke C, Zielinski CC (2004) Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 10: 1618-1624 (Pubitemid 38435551)
16. Leary AF, Hanna WM, van de Vijver MJ, Penault-Llorca F, Ruschoff J, Osamura RY, Bilous M, Dowsett M (2009) Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. J Clin Oncol 27: 1694-1705
17. Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, Harvey HA, Brady C, Nalin CM, Dugan M, Carney W, Allard J (2002) Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20: 1467-1472 (Pubitemid 34260524)
18. Lofts FJ, Gullick WJ (1992) c-erbB2 amplification and overexpression in human tumors. Cancer Treat Res 61: 161-179
19. Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, Maxwell GL, Fowler JM (2006) HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 24: 2376-2385 (Pubitemid 46630670)
20. Pupa SM, Ménard S, Morelli D, Pozzi B, De Palo G, Colnaghi MI (1993) The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 8: 2917-2923 (Pubitemid 23312894)
21. Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O'Brien T, Cannon MJ, Parham GP (2002) Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res 8: 1271-1279 (Pubitemid 34517668)
22. Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S (2008) Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynaecol Obstet 102: 128-131
23. Santin AD, Bellone S, Siegel ER, Palmieri M, Thomas M, Cannon MJ, Kay HH, Roman JJ, Burnett A, Pecorelli S (2005a) Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol 192: 813-818 (Pubitemid 40311274)
24. Santin AD, Bellone S, Van Stedum S, Bushen W, De Las Casas LE, Korourian S, Tian E, Roman JJ, Burnett A, Pecorelli S (2005b) Determination of HER2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol 98: 24-30 (Pubitemid 40826414)
25. Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S (2005c) Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer 104: 1391-1397 (Pubitemid 41356154)
26. Schwartz PE (2006) The management of serous papillary uterine cancer. Curr Opin Oncol 18: 494-499 (Pubitemid 44199847)
27. Scott GK, Robles R, Park JW, Montgomery PA, Daniel J, Holmes WE, Lee J, Keller GA, Li WL, Fendly BM, Wood WI, Shepard HM, Benz CC (1993) A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol 13: 2247-2257 (Pubitemid 23097703)
28. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712 (Pubitemid 19147683)
29. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792 (Pubitemid 32222155)
30. Villella JA, Cohen S, Smith DH, Hibshoosh H, Hershman D (2006) HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int J Gynecol Cancer 16: 1897-1902 (Pubitemid 44470053)
31. Wright C, Angus B, Nicholson S, Sainsbury JR, Cairns J, Gullick WJ, Kelly P, Harris AL, Horne CH (1989) Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 49: 2087-2090 (Pubitemid 19106519)
32. Wu JT, Zhang P, Astill ME, Lyons BW, Wu LH (1995) Identification and characterization of c-erbB-2 proteins in serum, breast tumor tissue, and SK-BR-3 cell line. J Clin Lab Anal 9: 141-150
33. Zabrecky JR, Lam T, McKenzie SJ, Carney W (1991) The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 266: 1716-1720 (Pubitemid 21908361)